Merck has completed its $11.5 billion acquisition of Acceleron Pharma Inc., it announced Monday.
The deal, first announced in September, will see the Kenilworth-based drugmaker add the Massachusetts-based biopharma firm for $180 per share in cash.
“This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy,” Rob Davis, Merck’s CEO and president, said in a prepared statement.
Acceleron’s lead therapeutic candidate, sotatercept, is focused on helping patients with pulmonary arterial hypertension, a blood vessel disorder.
